AJP - Endocrinology and Metabolism, Vol 262, Issue 1 E130-E133, Copyright © 1992 by American Physiological Society

ARTICLES

Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism

S. D. Boulware, W. V. Tamborlane, L. S. Matthews and R. S. Sherwin
Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut 06510.

The metabolic effects of recombinant human insulin-like growth factor I (rhIGF-I) on glucose, amino acid, and free fatty acid (FFA) metabolism were examined in nine healthy nonobese subjects. Each received a 3-h primed continuous infusion of rhIGF-I (20 micrograms/kg bolus, 0.4 microgram.kg-1.min-1) while maintaining euglycemia using an exogenous glucose infusion. Total IGF-I levels increased from 125 +/- 11 to 444 +/- 22 ng/ml, and free IGF-I levels rose from undetectable to 73 +/- 5 ng/ml. Insulin levels fell from 95 +/- 9 to 64 +/- 8 pM, and C-peptide fell from 453 +/- 48 to 206 +/- 29 pM; circulating glucagon levels also declined from 72 +/- 9 to 42 +/- 4 pg/ml, rhIGF-I produced a two- to threefold increase in glucose uptake as measured by [3H] glucose (from 10.3 +/- 0.6 to 27.4 +/- 3 mumol.kg-1.m-1), and, despite the fall in insulin secretion, there was a marked 60-70% inhibition of hepatic glucose production. Furthermore, FFA and branched-chain amino acids declined by 40-60% (411 +/- 58 to 165 +/- 36 and 406 +/- 23 to 219 +/- 14 microM, respectively). Our data demonstrate that rhIGF-I has potent effects on glucose (hepatic and peripheral), lipid, and amino acid metabolism in normal humans. The scope of the actions of rhIGF-I closely resemble those of insulin, despite a concomitant inhibitory effect on insulin secretion.

This article has been cited by other articles:

				C. H. Lang, R. A. Frost, E. Svanberg, and T. C. Vary IGF-I/IGFBP-3 ameliorates alterations in protein synthesis, eIF4E availability, and myostatin in alcohol-fed rats Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E916 - E926. [Abstract] [Full Text] [PDF]

				C. Vecchione, S. Colella, L. Fratta, M. T. Gentile, G. Selvetella, G. Frati, B. Trimarco, and G. Lembo Impaired Insulin-Like Growth Factor I Vasorelaxant Effects in Hypertension Hypertension, June 1, 2001; 37(6): 1480 - 1485. [Abstract] [Full Text] [PDF]

				C. M. CHENG, M. COHEN, J. WANG, and C. A. BONDY Estrogen augments glucose transporter and IGF1 expression in primate cerebral cortex FASEB J, April 1, 2001; 15(6): 907 - 915. [Abstract] [Full Text] [PDF]

				A. Bayes-Genis, C. A. Conover, and R. S. Schwartz The Insulin-Like Growth Factor Axis : A Review of Atherosclerosis and Restenosis Circ. Res., February 4, 2000; 86(2): 125 - 130. [Abstract] [Full Text] [PDF]

				L. H. Young, Y. Renfu, X. Hu, S. Chong, S. Hasan, R. Jacob, and R. S. Sherwin Insulin-like growth factor I stimulates cardiac myosin heavy chain and actin synthesis in the awake rat Am J Physiol Endocrinol Metab, January 1, 1999; 276(1): E143 - E150. [Abstract] [Full Text] [PDF]

				C.-H. Fang, B.-G. Li, J. J. Wang, J. E. Fischer, and P.-O. Hasselgren Treatment of burned rats with insulin-like growth factor I inhibits the catabolic response in skeletal muscle Am J Physiol Regulatory Integrative Comp Physiol, October 1, 1998; 275(4): R1091 - R1098. [Abstract] [Full Text] [PDF]

				K. F. Petersen, R. Jacob, A. B. West, R. S. Sherwin, and G. I. Shulman Effects of insulin-like growth factor I on glucose metabolism in rats with liver cirrhosis Am J Physiol Endocrinol Metab, December 1, 1997; 273(6): E1189 - E1193. [Abstract] [Full Text] [PDF]

				A M Taylor, A Bush, A Thomson, P J Oades, J L Marchant, C Bruce-Morgan, J Holly, L Ahmed, and D B Dunger Relation between insulin-like growth factor-I, body mass index, and clinical status in cystic fibrosis Arch. Dis. Child., April 1, 1997; 76(4): 304 - 309. [Abstract] [Full Text]